what is the maintenance dose of tirzepatide for Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN Tirzepatide Maintenance Dose for Weight

Based on Phase 2 safety data (Jastreboff et al., NEJM 2023), common early adverse effects reported include: Nausea (the most frequently reported adverse effect) Vomiting Diarrhoea or constipation Reduced appetite Mild fatigue or dizziness These effects are consistent with the GLP-1 receptor agonist class and typically reflect the gut's adaptation to altered gastric emptying and hormonal signalling

Regular monitoring by a healthcare provider is essential to manage and mitigate these effects

Some of the medications listed below are approved by the United States Food and Drug Administration (FDA) for weight loss, while others are prescribed off-label for this purpose

Goldin, R

This dual engagement provides an effective approach for managing blood sugar and weight